Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM3PSCA in advanced PSCA-positive cancers
NCT03927573Phase 1Terminated
- Sponsor
- AvenCell Therapeutics
- Start
- Apr 2019
- Primary completion
- Jun 2023
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of GEM3-PSCA in non-small cell lung cancer (NSCLC), prostate cancer (PCa), renal cell carcinoma (RCC) and 1 more, sponsored by AvenCell Therapeutics. Primary endpoints: Maximum Tolerated Dose, Incidence and intensity of adverse events and 1 more. Started Apr 2019; status: terminated.
02
Drugs
GEM3-PSCA
03
Conditions
non-small cell lung cancer (NSCLC)prostate cancer (PCa)renal cell carcinoma (RCC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NCT03927573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927573.